{"gene":"MME","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1991,"finding":"CD10/NEP (neutral endopeptidase 24.11) enzymatic activity on neutrophil cell surfaces hydrolyzes inflammatory peptides including f-MLP and substance P, thereby controlling neutrophil responsiveness; inhibition of CD10/NEP enzymatic activity potentiates f-MLP- and substance P-induced changes in neutrophil morphology, migration, and adhesion molecule expression (upregulation of Mo1/CD11b/CD18 and shedding of LAM-1). CD10/NEP enzymatic activity is itself regulated by the activation state of the neutrophil.","method":"Cell-based enzyme inhibition assays, flow cytometry for adhesion molecules, neutrophil migration assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays (inhibitor studies, migration, adhesion marker upregulation) in a focused mechanistic study; replicated conceptually across multiple inflammatory peptide substrates","pmids":["1717072"],"is_preprint":false},{"year":1989,"finding":"cALLA (CD10) expressed on glioma cell lines is enzymatically active neutral endopeptidase (NEP), as demonstrated by phosphoramidon-inhibitable endopeptidase activity and the presence of NEP-specific mRNA; surface expression of cALLA directly correlates with functional NEP enzymatic activity.","method":"Enzyme activity assay with phosphoramidon inhibition, immunostaining with anti-NEP and anti-cALLA antibodies, Northern blot for NEP mRNA","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic activity assay with specific inhibitor plus orthogonal molecular confirmation (mRNA, two antibody sets); replicated across 10 glioma cell lines","pmids":["2531122"],"is_preprint":false},{"year":1991,"finding":"CALLA (CD10) is structurally identical to neutral endopeptidase 3.4.24.11 (NEP); malignant leukemic cells express a functionally active NEP enzyme, and surface CD10 expression correlates with NEP enzymatic activity. No gross alteration in the CD10/CALLA gene was found in leukemic or malignant cell lines.","method":"Restriction enzyme hybridization (Southern blot), enzyme activity assays for NEP on leukemia samples and cell lines","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity correlated with surface expression across leukemia and multiple cell lines; single lab but orthogonal methods (molecular and biochemical)","pmids":["1833412"],"is_preprint":false},{"year":1994,"finding":"CD10/NEP modulates peptide-mediated proliferation of non-small cell lung carcinoma (NSCLC) cells; cells with lower CD10/NEP expression proliferate more rapidly, and inhibition of cell-surface CD10/NEP enzymatic activity increases cellular growth rate. CD10/NEP expression is inversely correlated with proliferating cell nuclear antigen (PCNA) expression, and NSCLC cells express receptors for mitogenic peptide substrates of CD10/NEP.","method":"Immunostaining for CD10/NEP and PCNA, cell proliferation assays with CD10/NEP inhibition, receptor characterization","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional proliferation assay with enzyme inhibition, correlated with PCNA marker; single lab with two orthogonal approaches","pmids":["7962523"],"is_preprint":false},{"year":1997,"finding":"CD10 (endopeptidase 24.11) expressed on thymic epithelial cell (TEC) lines cleaves the thymic peptide thymopentin-5 (TP5) at the cell surface, thereby modulating TP5-induced TEC proliferation. Phosphoramidon, a specific endopeptidase 24.11 inhibitor, acts in synergy with TP5 to enhance TEC growth, confirming that CD10-mediated TP5 cleavage limits TP5 mitogenic signaling.","method":"Enzyme inhibition with phosphoramidon, cell proliferation assays, peptide cleavage assays at TEC surface","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional enzyme activity and proliferation assays with specific inhibitor; single lab, two orthogonal methods","pmids":["9337153"],"is_preprint":false},{"year":1998,"finding":"Human cytomegalovirus (HCMV) infection downregulates CD10 (neutral endopeptidase) surface expression and enzyme activity; HCMV reduces CD10 mRNA levels, inhibits glycosylation of newly synthesized CD10 polypeptide chains, and decreases the rate of CD10 synthesis. Downregulation of CD10 by HCMV is independent of viral DNA synthesis (treatment with viral DNA synthesis inhibitor does not block CD10 downregulation), suggesting a mechanism distinct from that used for CD13 downregulation.","method":"Flow cytometry for surface expression, enzyme activity assays, metabolic labeling, RT-PCR/Northern blot for mRNA, inhibitor studies","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (surface expression, enzyme activity, mRNA, glycosylation, inhibitor dissection); single lab","pmids":["9792845"],"is_preprint":false},{"year":2000,"finding":"NEP/CD10 is expressed on syncytiotrophoblasts of normal placenta and in gestational trophoblastic diseases (GTDs). NEP enzyme activity in choriocarcinoma cell lines correlates with cell-surface NEP protein levels and is abolished by the NEP inhibitor phosphoramidon. NEP appears as a double band of 95 and 100 kDa in placental and GTD tissues. Differential localization of NEP among trophoblastic tumors (restricted to syncytiotrophoblasts in normal placenta and hydatidiform mole; extended to anaplastic cytotrophoblasts in choriocarcinoma) suggests a role in trophoblast transformation and hCG secretion.","method":"Flow cytometry, phosphoramidon enzyme inhibition assay, immunoblot (Western blot), immunohistochemistry","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity correlated with protein expression, inhibitor confirmation, multiple orthogonal methods; single lab","pmids":["11092533"],"is_preprint":false},{"year":2002,"finding":"NEP/CD10 expression is induced de novo on HL-60 cells upon jaspamide (jasplakinolide)-induced apoptosis. Once expressed, CD10 enzyme activity interferes with apoptotic signaling: inhibition of CD10 enzymatic activity (by phosphoramidon or anti-CD10 antibody) significantly increases apoptosis. CD10 expression is blocked by monocytic differentiating agents (vitamin D3, PMA) but not granulocytic agents, linking CD10 expression to granulocytic differentiation. A broad-spectrum caspase inhibitor partially blocks CD10 induction, suggesting a connection between apoptosis and CD10 synthesis.","method":"Flow cytometry, cycloheximide protein synthesis inhibition, enzyme inhibition (phosphoramidon, anti-CD10 antibody), caspase inhibitor studies, differentiation agent treatments","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological interventions with functional readouts; single lab","pmids":["12363040"],"is_preprint":false},{"year":2004,"finding":"Truncating mutations in the MME gene (encoding NEP/CD10) cause absence of NEP protein expression in affected mothers, leading to fetomaternal alloimmunization against fetal NEP antigens on glomerular podocytes during pregnancy. Two compound heterozygous or homozygous mutations were identified (1342C→T nonsense and 446delC frameshift). The severity of neonatal membranous glomerulopathy was determined by the maternal IgG response to fetal NEP, establishing NEP as the podocyte target antigen in antenatal membranous glomerulonephritis.","method":"Direct sequencing of genomic PCR products, SNP haplotype analysis, Western blotting for IgG subclasses with anti-NEP activity","journal":"Lancet","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct sequencing identified causative loss-of-function mutations, corroborated by protein absence and functional antibody data across multiple families; replicated in three independent families","pmids":["15464186"],"is_preprint":false},{"year":2010,"finding":"CD10 protease activity is required to prevent differentiation of human mammary progenitors: inhibition of CD10 enzymatic activity promotes differentiation. The CD10-high/EpCAM-low population is enriched for early common progenitors and mammosphere-forming cells. CD10 acts in concert with beta1-integrin adhesion to the basement membrane to maintain the mammary progenitor/stem cell pool.","method":"Cell sorting (FACS for CD10 and EpCAM), mammosphere formation assays, enzyme inhibition functional assays, in vitro lineage progression assay","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional enzyme inhibition assay with differentiation readout, combined with prospective cell sorting; single lab, two orthogonal approaches","pmids":["20506111"],"is_preprint":false},{"year":2010,"finding":"A common MME nonsynonymous variant (Val73) causes a significant reduction in MME enzyme activity (21% of wild-type) and immunoreactive NEP protein (29% of wild-type). Proteasome-mediated degradation and autophagy both participate in the degradation of this variant allozyme, and upregulation of chaperone proteins BiP and GRP94 after Val73 MME transfection indicates protein misfolding, consistent with MME X-ray crystal structural predictions.","method":"COS-1 cell transfection, quantitative Western blot, fluorometric enzyme activity assay, proteasome/autophagy inhibitor studies, chaperone protein analysis","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis (variant allozyme expression), enzymatic activity assay, protein degradation pathway dissection with inhibitors, and chaperone upregulation; multiple orthogonal methods in single rigorous study","pmids":["20692264"],"is_preprint":false},{"year":2013,"finding":"CD10 is selectively associated with tetraspanin CD9 (but not CD82) on the cell surface. Stable expression of wild-type CD9 in CD10-positive K562 cells enhances CD10 release with exosomes five-fold, whereas CD9 chimera containing the CD82 C-terminal tail has little effect. ShRNA knockdown of CD9 in Nalm-6 pre-B cells reduces endogenous CD10 release in microvesicles two-fold. CD10 peptidase activity correlates with CD10 expression level and is not significantly modulated by CD9 expression per se.","method":"Co-immunoprecipitation, chimeric tetraspanin mutagenesis, shRNA knockdown, exosome isolation and quantification, peptidase activity assay","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — binding partner identified by Co-IP and mapped by mutagenesis/chimera studies; functional consequence (exosome release) validated by both overexpression and knockdown; enzymatic activity measured independently","pmids":["23289620"],"is_preprint":false},{"year":2016,"finding":"Recessive loss-of-function mutations in MME (encoding neprilysin/NEP) cause autosomal-recessive Charcot-Marie-Tooth type 2 (AR-CMT2T) with late-onset axonal neuropathy; lack/decrease of NEP protein expression was confirmed in peripheral nerve tissue of affected patients. All MME mutations identified were consistent with loss-of-function. The loss-of-function MME mutation did not cause early-onset Alzheimer's disease in affected individuals.","method":"Whole-exome sequencing, Sanger sequencing mutation confirmation, immunohistochemical protein expression in peripheral nerve, clinico-pathological characterization","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function variants identified in 10 unrelated patients, protein absence confirmed in nerve tissue; replicated across multiple independent families","pmids":["26991897"],"is_preprint":false},{"year":2016,"finding":"Rare heterozygous loss-of-function and missense mutations in MME (neprilysin) cause late-onset autosomal-dominant axonal polyneuropathies with age-related incomplete penetrance. MME mutations result in strongly decreased tissue availability of neprilysin and impaired enzymatic activity in affected individuals.","method":"Whole-exome sequencing, Sanger sequencing, nerve tissue neprilysin level measurement, enzymatic activity assay in patient tissue","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutations identified in 19 independent index cases, protein level and enzymatic activity directly measured in patient tissues; replicated across multiple labs/cohorts","pmids":["27588448"],"is_preprint":false},{"year":2016,"finding":"A heterozygous MME missense mutation (p.C143Y), affecting a conserved cysteine involved in a disulfide bridge of neprilysin, segregates with dominant spinocerebellar ataxia and polyneuropathy (SCA43) in a five-generation Belgian family, indicating that disruption of this structural disulfide bridge causes dominant disease.","method":"Linkage analysis, whole-exome sequencing, Sanger sequencing cosegregation analysis, bioinformatic conservation analysis","journal":"Neurology Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic cosegregation in single family with structural prediction; no direct functional protein characterization performed in this paper","pmids":["27583304"],"is_preprint":false},{"year":2019,"finding":"MME (neprilysin/CD10) inhibits esophageal squamous cell carcinoma (ESCC) metastasis by inhibiting FAK phosphorylation and thereby disrupting the FAK-RhoA signaling axis, which is important for cell movement. MME overexpression also interrupts ESCC tumor cell adhesion.","method":"In vitro and in vivo metastasis assays, Western blot for FAK phosphorylation, RhoA pathway analysis, MME overexpression functional studies","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional overexpression studies with defined molecular readout (FAK phosphorylation, RhoA axis) confirmed in vitro and in vivo; single lab","pmids":["31054987"],"is_preprint":false},{"year":2019,"finding":"CD10 expression identifies a subset of human adventitial perivascular progenitor cells (CD10+ adventitial cells) with higher proliferation, clonogenic, and osteogenic potentials compared to CD10- counterparts. CD10+ adventitial cells increase expression of cell cycle protein CCND2 via ERK1/2 signaling and osteoblastogenic gene expression via NF-κB signaling. CD10 expression in adventitial cells is upregulated through sonic hedgehog-mediated GLI1 signaling.","method":"Cell sorting, clonogenic assays, osteogenic differentiation assays, Western blotting for ERK1/2 and NF-κB pathway components, hedgehog pathway inhibition","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell sorting with functional comparison, pathway inhibition studies; single lab with multiple orthogonal assays","pmids":["31721342"],"is_preprint":false},{"year":2020,"finding":"MME variants are the most frequently identified genetic cause of late-onset unexplained axonal neuropathies, accounting for 34.8% of genetically solved cases; transmission is consistent with incompletely penetrant autosomal-dominant inheritance. Low neprilysin blood levels were confirmed in patients with MME variants, supporting a loss-of-function mechanism.","method":"Whole-exome sequencing, MME single-gene sequencing, blood neprilysin protein level measurement","journal":"Neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-center study with independent replication cohort; direct protein level measurement in patients; consistent with prior studies","pmids":["33144514"],"is_preprint":false},{"year":2023,"finding":"An MME+ fibro-adipogenic progenitor (FAP) subpopulation has high adipogenic potential and low WNT pathway activity, making it refractory to WNT activator-mediated inhibition of adipogenic commitment. Transplantation experiments confirmed that MME+ FAPs preferentially differentiate into adipocytes under pathological conditions, and MME+ FAPs undergo apoptosis during muscle regeneration, reducing their abundance.","method":"Single-nuclei and single-cell RNA sequencing, ex vivo cell characterization, transplantation experiments, WNT pathway inhibitor/activator studies","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transplantation experiments confirm adipogenic fate, WNT pathway mechanistic link shown; single lab with scRNA-seq and functional validation","pmids":["36707617"],"is_preprint":false},{"year":2004,"finding":"Inhibition of CD10 enzymatic activity significantly reduced the growth of gastric cancer cell lines MKN28 and AGS, demonstrating that CD10's ability to degrade gastrointestinal peptides plays a role in gastric cancer cell proliferation.","method":"Cell proliferation assays with enzyme inhibition","journal":"International journal of oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single pharmacological inhibition assay in cell lines; no mechanistic follow-up on substrate identity","pmids":["15492809"],"is_preprint":false}],"current_model":"MME encodes neprilysin (NEP/CD10), a zinc-dependent cell-surface metalloprotease that cleaves a broad range of bioactive peptides (enkephalins, substance P, f-MLP, natriuretic peptides, thymopentin, amyloid-β) at the cell surface to attenuate peptide-mediated signaling; its enzymatic activity controls neutrophil inflammatory responsiveness, mammary progenitor differentiation, lung and gastric carcinoma cell proliferation, and trophoblast biology; interaction with tetraspanin CD9 regulates CD10 exosomal release; loss-of-function MME mutations cause peripheral neuropathy (AR-CMT2T and dominant late-onset polyneuropathy) by reducing neprilysin protein levels and enzymatic activity; and MME suppresses cancer cell metastasis via inhibition of FAK-RhoA signaling, while variant allozymes are degraded by proteasomal and autophagic pathways."},"narrative":{"mechanistic_narrative":"MME encodes neprilysin (NEP/CD10/CALLA), a zinc-dependent cell-surface neutral endopeptidase (EC 3.4.24.11) whose phosphoramidon-inhibitable enzymatic activity cleaves bioactive peptides at the plasma membrane to attenuate peptide-mediated signaling across diverse cell types [PMID:2531122, PMID:1833412]. On neutrophils, surface NEP hydrolyzes inflammatory peptides such as f-MLP and substance P, and inhibiting its activity potentiates peptide-driven migration and adhesion-molecule changes (CD11b/CD18 upregulation, LAM-1 shedding), establishing NEP as a brake on inflammatory responsiveness [PMID:1717072]. The same catalytic mechanism limits peptide-mitogen signaling to constrain proliferation: NEP cleaves thymopentin to restrain thymic epithelial cell growth [PMID:9337153], and its inhibition or loss accelerates non-small-cell lung carcinoma and gastric carcinoma proliferation [PMID:7962523]. NEP also regulates cell-fate decisions, maintaining mammary progenitors in an undifferentiated state through its protease activity acting together with beta1-integrin adhesion [PMID:20692264], and it suppresses esophageal squamous carcinoma metastasis by inhibiting FAK phosphorylation and the downstream FAK-RhoA motility axis [PMID:31054987]. NEP associates selectively with the tetraspanin CD9, which promotes its release in exosomes/microvesicles without altering its intrinsic peptidase activity [PMID:23289620]. Loss-of-function MME mutations cause late-onset axonal peripheral neuropathy through both autosomal-recessive (AR-CMT2T) and incompletely penetrant autosomal-dominant inheritance, with reduced neprilysin protein and enzymatic activity confirmed in patient nerve and blood [PMID:26991897, PMID:27588448, PMID:33144514]; truncating maternal mutations also underlie antenatal membranous glomerulonephritis via fetomaternal alloimmunization against podocyte NEP [PMID:15464186]. A common Val73 variant allozyme misfolds and is degraded by proteasomal and autophagic pathways with chaperone (BiP/GRP94) induction, providing a molecular basis for reduced enzyme availability [PMID:20692264].","teleology":[{"year":1989,"claim":"Established that the leukemia/glioma surface antigen CD10/cALLA is itself an enzymatically active neutral endopeptidase, unifying an immunophenotypic marker with a defined catalytic activity.","evidence":"Phosphoramidon-inhibitable endopeptidase assay, anti-NEP/anti-cALLA immunostaining, and NEP mRNA Northern blot across glioma cell lines","pmids":["2531122","1833412"],"confidence":"High","gaps":["Did not enumerate the physiological peptide substrates in these cells","Structural basis of catalysis not addressed"]},{"year":1991,"claim":"Defined NEP/CD10 as a regulator of neutrophil inflammatory responsiveness by degrading chemotactic and inflammatory peptides at the cell surface.","evidence":"Cell-based enzyme inhibition with migration and adhesion-molecule (CD11b/CD18, LAM-1) flow cytometry readouts in neutrophils","pmids":["1717072"],"confidence":"High","gaps":["Did not identify which substrate dominates in vivo","Mechanism coupling neutrophil activation state to NEP activity unresolved"]},{"year":1994,"claim":"Extended the peptide-degradation logic to a growth-control role, showing NEP limits peptide-mitogen-driven proliferation of carcinoma cells.","evidence":"CD10/NEP inhibition proliferation assays inversely correlated with PCNA in NSCLC; gastric cancer lines confirmed pharmacologically","pmids":["7962523","15492809"],"confidence":"Medium","gaps":["Specific mitogenic substrate not definitively identified","Gastric finding rests on a single inhibition assay"]},{"year":1997,"claim":"Provided substrate-resolved evidence that NEP cleavage of a defined peptide (thymopentin) tunes cell proliferation.","evidence":"Phosphoramidon synergy with TP5 and surface peptide-cleavage assays in thymic epithelial cell lines","pmids":["9337153"],"confidence":"Medium","gaps":["Downstream TP5 receptor signaling not mapped","Single cell-line system"]},{"year":2004,"claim":"Demonstrated in humans that complete loss of NEP protein has pathological consequences, identifying NEP as the podocyte antigen in antenatal membranous glomerulonephritis.","evidence":"Genomic sequencing of truncating MME mutations in mothers plus anti-NEP IgG subclass analysis across families","pmids":["15464186"],"confidence":"High","gaps":["Does not address NEP catalytic role in the kidney","Penetrance of alloimmunization not quantified"]},{"year":2010,"claim":"Linked a common MME coding variant to reduced enzyme availability via protein misfolding and degradation, giving a mechanistic basis for functional NEP deficiency.","evidence":"COS-1 expression of Val73 allozyme with quantitative Western blot, fluorometric activity assay, proteasome/autophagy inhibitors, and BiP/GRP94 analysis","pmids":["20692264"],"confidence":"High","gaps":["Physiological/clinical penetrance of the variant not established here","Folding defect inferred from crystal-structure prediction, not directly imaged"]},{"year":2010,"claim":"Showed NEP protease activity actively maintains the mammary progenitor pool, expanding its role from signal attenuation to stem-cell fate control.","evidence":"FACS isolation of CD10-high/EpCAM-low cells, mammosphere assays, and enzyme inhibition driving differentiation","pmids":["20506111"],"confidence":"Medium","gaps":["Relevant cleaved substrate maintaining progenitors unknown","Mechanistic interplay with beta1-integrin not molecularly resolved"]},{"year":2013,"claim":"Identified the tetraspanin CD9 as a direct surface partner controlling NEP packaging into exosomes/microvesicles, separating trafficking from intrinsic catalysis.","evidence":"Co-IP, CD9/CD82 chimera mutagenesis, shRNA knockdown, and exosome quantification with independent peptidase assays","pmids":["23289620"],"confidence":"High","gaps":["Functional consequence of NEP exosomal release on recipient cells not tested","CD9-binding interface on NEP not mapped"]},{"year":2016,"claim":"Established MME loss-of-function as a genetic cause of late-onset axonal neuropathy through both recessive and dominant, incompletely penetrant inheritance, with NEP reduction confirmed in patient nerve.","evidence":"Whole-exome/Sanger sequencing across multiple cohorts plus immunohistochemical and enzymatic confirmation in peripheral nerve; one family showed a disulfide-disrupting p.C143Y in SCA43","pmids":["26991897","27588448","27583304"],"confidence":"High","gaps":["NEP substrate(s) relevant to axonal maintenance not identified","Basis of incomplete penetrance unresolved","C143Y functional consequence inferred from structure, not assayed"]},{"year":2019,"claim":"Defined a non-proteolytic-context tumor-suppressor mechanism in which MME restrains metastasis by inhibiting FAK-RhoA signaling and cell adhesion.","evidence":"MME overexpression in vitro/in vivo metastasis assays with Western blot for FAK phosphorylation and RhoA pathway analysis in ESCC","pmids":["31054987"],"confidence":"Medium","gaps":["Whether enzymatic activity is required for FAK inhibition not dissected","Single cancer-type, single lab"]},{"year":2023,"claim":"Positioned MME as a marker of progenitor subpopulations with distinct fate biases, including adipogenic FAPs refractory to WNT-mediated suppression and CD10+ adventitial osteogenic progenitors.","evidence":"scRNA/snRNA-seq, transplantation, and WNT/hedgehog pathway perturbation in FAP and adventitial progenitor systems","pmids":["36707617","31721342"],"confidence":"Medium","gaps":["Whether NEP enzymatic activity drives these fate outcomes or is merely a marker is unclear","Substrates relevant to FAP/adventitial biology not identified"]},{"year":null,"claim":"The physiological substrate(s) of neprilysin whose accumulation drives axonal neuropathy, and whether catalytic versus scaffolding functions account for its progenitor and tumor-suppressor roles, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined substrate links NEP loss to axon degeneration","Catalytic vs non-catalytic contribution to FAK-RhoA inhibition and progenitor maintenance not separated","No structural model of NEP-CD9 or variant misfolding directly validated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,2,4,6]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,6,11]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10,16,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,12,13,17]}],"complexes":[],"partners":["CD9"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08473","full_name":"Neprilysin","aliases":["Atriopeptidase","Common acute lymphocytic leukemia antigen","CALLA","Enkephalinase","Neutral endopeptidase 24.11","NEP","Neutral endopeptidase","Skin fibroblast elastase","SFE"],"length_aa":750,"mass_kda":85.5,"function":"Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:6208535, PubMed:6349683, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991, PubMed:6349683). Catalyzes cleavage of bradykinin, substance P and neurotensin peptides (PubMed:6208535). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675, PubMed:6349683). Involved in the degradation of atrial natriuretic factor (ANF) and brain natriuretic factor (BNP(1-32)) (PubMed:16254193, PubMed:2531377, PubMed:2972276). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers (PubMed:20876573)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P08473/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MME","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MME","total_profiled":1310},"omim":[{"mim_id":"618366","title":"VPS8 CORVET COMPLEX SUBUNIT; VPS8","url":"https://www.omim.org/entry/618366"},{"mim_id":"618104","title":"MEMBRANE METALLOENDOPEPTIDASE-LIKE 1; MMEL1","url":"https://www.omim.org/entry/618104"},{"mim_id":"617018","title":"SPINOCEREBELLAR ATAXIA 43; SCA43","url":"https://www.omim.org/entry/617018"},{"mim_id":"617017","title":"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T","url":"https://www.omim.org/entry/617017"},{"mim_id":"614692","title":"MEMBRANOUS NEPHROPATHY, SUSCEPTIBILITY TO; MBNP","url":"https://www.omim.org/entry/614692"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Centrosome","reliability":"Approved"},{"location":"Basal body","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":314.1},{"tissue":"kidney","ntpm":282.6}],"url":"https://www.proteinatlas.org/search/MME"},"hgnc":{"alias_symbol":["CALLA","CD10","NEP"],"prev_symbol":[]},"alphafold":{"accession":"P08473","domains":[{"cath_id":"3.40.390.10","chopping":"61-95_433-484_536-734","consensus_level":"medium","plddt":98.1686,"start":61,"end":734},{"cath_id":"1.10.1380.10","chopping":"157-383","consensus_level":"high","plddt":98.496,"start":157,"end":383}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08473","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08473-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08473-F1-predicted_aligned_error_v6.png","plddt_mean":96.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MME","jax_strain_url":"https://www.jax.org/strain/search?query=MME"},"sequence":{"accession":"P08473","fasta_url":"https://rest.uniprot.org/uniprotkb/P08473.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08473/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08473"}},"corpus_meta":[{"pmid":"29395328","id":"PMC_29395328","title":"CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29395328","citation_count":1013,"is_preprint":false},{"pmid":"28053192","id":"PMC_28053192","title":"Mature CD10+ and immature CD10- neutrophils present in G-CSF-treated donors display opposite effects on T cells.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28053192","citation_count":267,"is_preprint":false},{"pmid":"10843287","id":"PMC_10843287","title":"CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.","date":"2000","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10843287","citation_count":243,"is_preprint":false},{"pmid":"6973348","id":"PMC_6973348","title":"Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.","date":"1981","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/6973348","citation_count":240,"is_preprint":false},{"pmid":"38039991","id":"PMC_38039991","title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.","date":"2023","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38039991","citation_count":171,"is_preprint":false},{"pmid":"1717072","id":"PMC_1717072","title":"CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation.","date":"1991","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1717072","citation_count":159,"is_preprint":false},{"pmid":"15464186","id":"PMC_15464186","title":"Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies.","date":"2004","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15464186","citation_count":144,"is_preprint":false},{"pmid":"11781522","id":"PMC_11781522","title":"CD10 is a marker for normal and neoplastic endometrial stromal cells.","date":"2002","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/11781522","citation_count":120,"is_preprint":false},{"pmid":"15502805","id":"PMC_15502805","title":"Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study.","date":"2005","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15502805","citation_count":113,"is_preprint":false},{"pmid":"17138820","id":"PMC_17138820","title":"CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17138820","citation_count":106,"is_preprint":false},{"pmid":"37689322","id":"PMC_37689322","title":"Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37689322","citation_count":101,"is_preprint":false},{"pmid":"12203213","id":"PMC_12203213","title":"Expression of CD10 by stromal cells during colorectal tumor development.","date":"2002","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12203213","citation_count":93,"is_preprint":false},{"pmid":"23289620","id":"PMC_23289620","title":"Tetraspanin protein CD9 interacts with metalloprotease CD10 and enhances its release via exosomes.","date":"2013","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23289620","citation_count":92,"is_preprint":false},{"pmid":"26991897","id":"PMC_26991897","title":"Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26991897","citation_count":83,"is_preprint":false},{"pmid":"2957002","id":"PMC_2957002","title":"Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal marrow CALLA-positive B cell precursors.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2957002","citation_count":78,"is_preprint":false},{"pmid":"18545147","id":"PMC_18545147","title":"Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.","date":"2008","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18545147","citation_count":72,"is_preprint":false},{"pmid":"11583969","id":"PMC_11583969","title":"cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11583969","citation_count":70,"is_preprint":false},{"pmid":"12579992","id":"PMC_12579992","title":"B-cell lymphomas with coexpression of CD5 and CD10.","date":"2003","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12579992","citation_count":70,"is_preprint":false},{"pmid":"20506111","id":"PMC_20506111","title":"The CD10 enzyme is a key player to identify and regulate human mammary stem cells.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/20506111","citation_count":67,"is_preprint":false},{"pmid":"17448198","id":"PMC_17448198","title":"Immunohistochemical staining of CD10 in atypical fibroxanthomas.","date":"2007","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17448198","citation_count":64,"is_preprint":false},{"pmid":"14707864","id":"PMC_14707864","title":"CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma.","date":"2004","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14707864","citation_count":62,"is_preprint":false},{"pmid":"15618927","id":"PMC_15618927","title":"Expression of CD10 in basal cell carcinoma.","date":"2004","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/15618927","citation_count":61,"is_preprint":false},{"pmid":"36707617","id":"PMC_36707617","title":"MME+ fibro-adipogenic progenitors are the dominant adipogenic population during fatty infiltration in human skeletal muscle.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36707617","citation_count":59,"is_preprint":false},{"pmid":"7962523","id":"PMC_7962523","title":"CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation.","date":"1994","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/7962523","citation_count":56,"is_preprint":false},{"pmid":"16420307","id":"PMC_16420307","title":"CD10 expression in trichoepithelioma and basal cell carcinoma.","date":"2006","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16420307","citation_count":55,"is_preprint":false},{"pmid":"6225802","id":"PMC_6225802","title":"Distribution and modulation of a human leukemia-associated antigen (CALLA).","date":"1983","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/6225802","citation_count":54,"is_preprint":false},{"pmid":"11392883","id":"PMC_11392883","title":"Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas.","date":"2001","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11392883","citation_count":53,"is_preprint":false},{"pmid":"15492809","id":"PMC_15492809","title":"The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15492809","citation_count":53,"is_preprint":false},{"pmid":"17335564","id":"PMC_17335564","title":"Differential expression of CD10 in prostate cancer and its clinical implication.","date":"2007","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/17335564","citation_count":52,"is_preprint":false},{"pmid":"12218209","id":"PMC_12218209","title":"Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.","date":"2002","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/12218209","citation_count":52,"is_preprint":false},{"pmid":"34654055","id":"PMC_34654055","title":"Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34654055","citation_count":49,"is_preprint":false},{"pmid":"9625422","id":"PMC_9625422","title":"CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles.","date":"1998","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9625422","citation_count":49,"is_preprint":false},{"pmid":"27588448","id":"PMC_27588448","title":"Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27588448","citation_count":47,"is_preprint":false},{"pmid":"19826251","id":"PMC_19826251","title":"BCL6, MUM1, and CD10 expression in mantle cell lymphoma.","date":"2010","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/19826251","citation_count":47,"is_preprint":false},{"pmid":"27583304","id":"PMC_27583304","title":"MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43).","date":"2016","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27583304","citation_count":47,"is_preprint":false},{"pmid":"15794857","id":"PMC_15794857","title":"CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.","date":"2005","source":"Clinical lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/15794857","citation_count":45,"is_preprint":false},{"pmid":"15677540","id":"PMC_15677540","title":"Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours.","date":"2005","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15677540","citation_count":45,"is_preprint":false},{"pmid":"18518902","id":"PMC_18518902","title":"Mantle cell lymphoma with aberrant expression of CD10.","date":"2008","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/18518902","citation_count":43,"is_preprint":false},{"pmid":"24009629","id":"PMC_24009629","title":"The Expression of CD10 and CD15 Is Progressively Increased during Colorectal Cancer Development.","date":"2013","source":"Korean journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24009629","citation_count":43,"is_preprint":false},{"pmid":"22300665","id":"PMC_22300665","title":"EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence.","date":"2012","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22300665","citation_count":42,"is_preprint":false},{"pmid":"16084948","id":"PMC_16084948","title":"CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry.","date":"2005","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16084948","citation_count":42,"is_preprint":false},{"pmid":"20574156","id":"PMC_20574156","title":"Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence.","date":"2010","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20574156","citation_count":41,"is_preprint":false},{"pmid":"1392343","id":"PMC_1392343","title":"The increase of low density subpopulations and CD10 (CALLA) negative neutrophils in severely infected patients.","date":"1992","source":"Surgery today","url":"https://pubmed.ncbi.nlm.nih.gov/1392343","citation_count":40,"is_preprint":false},{"pmid":"15505532","id":"PMC_15505532","title":"CD10 expression in the female genital tract: does it have useful diagnostic applications?","date":"2004","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15505532","citation_count":39,"is_preprint":false},{"pmid":"26414904","id":"PMC_26414904","title":"CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.","date":"2015","source":"Cancer cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/26414904","citation_count":36,"is_preprint":false},{"pmid":"31721342","id":"PMC_31721342","title":"CD10 expression identifies a subset of human perivascular progenitor cells with high proliferation and calcification potentials.","date":"2019","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/31721342","citation_count":36,"is_preprint":false},{"pmid":"12363040","id":"PMC_12363040","title":"Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells.","date":"2002","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/12363040","citation_count":36,"is_preprint":false},{"pmid":"12931553","id":"PMC_12931553","title":"Analysis of CD10+ hairy cell leukemia.","date":"2003","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12931553","citation_count":35,"is_preprint":false},{"pmid":"8292887","id":"PMC_8292887","title":"Expression of CALLA/CD10 on human melanoma cells.","date":"1993","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/8292887","citation_count":34,"is_preprint":false},{"pmid":"13679451","id":"PMC_13679451","title":"Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas.","date":"2003","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/13679451","citation_count":34,"is_preprint":false},{"pmid":"21499231","id":"PMC_21499231","title":"CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma.","date":"2011","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/21499231","citation_count":31,"is_preprint":false},{"pmid":"22493749","id":"PMC_22493749","title":"Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.","date":"2012","source":"International journal of molecular epidemiology and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22493749","citation_count":31,"is_preprint":false},{"pmid":"15901128","id":"PMC_15901128","title":"Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms.","date":"2005","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/15901128","citation_count":30,"is_preprint":false},{"pmid":"37277751","id":"PMC_37277751","title":"FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37277751","citation_count":29,"is_preprint":false},{"pmid":"23348903","id":"PMC_23348903","title":"Prostate cancer cell phenotypes based on AGR2 and CD10 expression.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/23348903","citation_count":29,"is_preprint":false},{"pmid":"9175328","id":"PMC_9175328","title":"CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucémies).","date":"1997","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/9175328","citation_count":28,"is_preprint":false},{"pmid":"33144514","id":"PMC_33144514","title":"The genetic landscape of axonal neuropathies in the middle-aged and elderly: Focus on MME.","date":"2020","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33144514","citation_count":27,"is_preprint":false},{"pmid":"31054987","id":"PMC_31054987","title":"Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.","date":"2019","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31054987","citation_count":27,"is_preprint":false},{"pmid":"29306324","id":"PMC_29306324","title":"Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29306324","citation_count":27,"is_preprint":false},{"pmid":"28628241","id":"PMC_28628241","title":"Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.","date":"2017","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/28628241","citation_count":26,"is_preprint":false},{"pmid":"37583695","id":"PMC_37583695","title":"Ferroptosis of CD163+ tissue-infiltrating macrophages and CD10+ PC+ epithelial cells in lupus nephritis.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37583695","citation_count":26,"is_preprint":false},{"pmid":"17207277","id":"PMC_17207277","title":"Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.","date":"2007","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17207277","citation_count":26,"is_preprint":false},{"pmid":"20692264","id":"PMC_20692264","title":"Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.","date":"2010","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/20692264","citation_count":25,"is_preprint":false},{"pmid":"14757368","id":"PMC_14757368","title":"Expression of CD13/aminopeptidase N and CD10/neutral endopeptidase on cultured human keratinocytes.","date":"2004","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/14757368","citation_count":25,"is_preprint":false},{"pmid":"9792845","id":"PMC_9792845","title":"Human cytomegalovirus infection downregulates expression of the cellular aminopeptidases CD10 and CD13.","date":"1998","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/9792845","citation_count":23,"is_preprint":false},{"pmid":"32070494","id":"PMC_32070494","title":"Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32070494","citation_count":23,"is_preprint":false},{"pmid":"15517363","id":"PMC_15517363","title":"CD10 expression in diffuse large B-cell lymphomas does not influence survival.","date":"2004","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15517363","citation_count":22,"is_preprint":false},{"pmid":"19437324","id":"PMC_19437324","title":"CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome.","date":"2009","source":"Pediatric hematology and oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19437324","citation_count":21,"is_preprint":false},{"pmid":"18092952","id":"PMC_18092952","title":"CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis.","date":"2007","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/18092952","citation_count":21,"is_preprint":false},{"pmid":"2531122","id":"PMC_2531122","title":"Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.","date":"1989","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/2531122","citation_count":21,"is_preprint":false},{"pmid":"12122282","id":"PMC_12122282","title":"CD10 expression in non-small cell lung cancer.","date":"2002","source":"Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12122282","citation_count":20,"is_preprint":false},{"pmid":"27456402","id":"PMC_27456402","title":"CD10-(CALLA)-Positive Lymphocytes in Myeloma: Evidence that they are a Malignant Precursor Population and are of Germinal Centre Origin.","date":"1989","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/27456402","citation_count":20,"is_preprint":false},{"pmid":"29938548","id":"PMC_29938548","title":"CD10, TDAG51, CK20, AR, INSM1, and Nestin Expression in the Differential Diagnosis of Trichoblastoma and Basal Cell Carcinoma.","date":"2018","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29938548","citation_count":20,"is_preprint":false},{"pmid":"28831700","id":"PMC_28831700","title":"Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort.","date":"2017","source":"The journal of headache and pain","url":"https://pubmed.ncbi.nlm.nih.gov/28831700","citation_count":20,"is_preprint":false},{"pmid":"2959309","id":"PMC_2959309","title":"Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression.","date":"1987","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/2959309","citation_count":20,"is_preprint":false},{"pmid":"2968812","id":"PMC_2968812","title":"Decreased expression of the common acute lymphoblastic leukaemia antigen (CALLA/CD10) on neutrophils from patients with thermal injury.","date":"1988","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/2968812","citation_count":19,"is_preprint":false},{"pmid":"22279463","id":"PMC_22279463","title":"CD10 expression helps to differentiate basal cell carcinoma from trichoepithelioma.","date":"2011","source":"Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22279463","citation_count":19,"is_preprint":false},{"pmid":"12649673","id":"PMC_12649673","title":"Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.","date":"2003","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/12649673","citation_count":19,"is_preprint":false},{"pmid":"31943331","id":"PMC_31943331","title":"CD10 and p63 expression in a sarcomatoid undifferentiated melanoma: A cautionary (and molecularly annotated) tale.","date":"2020","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31943331","citation_count":18,"is_preprint":false},{"pmid":"38389922","id":"PMC_38389922","title":"A comprehensive review of the literature on CD10: its function, clinical application, and prospects.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38389922","citation_count":17,"is_preprint":false},{"pmid":"12171495","id":"PMC_12171495","title":"CD10 expression in primary intestinal large B-cell lymphomas: its clinical significance.","date":"2002","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12171495","citation_count":17,"is_preprint":false},{"pmid":"11092533","id":"PMC_11092533","title":"The expression and localization of neutral endopeptidase 24.11/CD10 in human gestational trophoblastic diseases.","date":"2000","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11092533","citation_count":17,"is_preprint":false},{"pmid":"26386615","id":"PMC_26386615","title":"Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma.","date":"2015","source":"European annals of otorhinolaryngology, head and neck diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26386615","citation_count":16,"is_preprint":false},{"pmid":"21609487","id":"PMC_21609487","title":"CD10 and osteopontin expression in dentigerous cyst and ameloblastoma.","date":"2011","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21609487","citation_count":16,"is_preprint":false},{"pmid":"2959334","id":"PMC_2959334","title":"Identification and characterization of a unique subpopulation (CALLA/CD10/negative) of human neutrophils manifesting a heightened chemotactic response to activated complement.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2959334","citation_count":16,"is_preprint":false},{"pmid":"27513891","id":"PMC_27513891","title":"CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine.","date":"2016","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/27513891","citation_count":16,"is_preprint":false},{"pmid":"22464152","id":"PMC_22464152","title":"Anti-CD10 (56C6) expression in soft tissue sarcomas.","date":"2012","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/22464152","citation_count":16,"is_preprint":false},{"pmid":"23063927","id":"PMC_23063927","title":"Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.","date":"2012","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/23063927","citation_count":16,"is_preprint":false},{"pmid":"33037760","id":"PMC_33037760","title":"Cancer stemness of CD10-positive cells regulated by Hedgehog pathway promotes the resistance to cisplatin in oral squamous cell carcinoma.","date":"2020","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33037760","citation_count":16,"is_preprint":false},{"pmid":"25759539","id":"PMC_25759539","title":"Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25759539","citation_count":15,"is_preprint":false},{"pmid":"16400325","id":"PMC_16400325","title":"CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16400325","citation_count":15,"is_preprint":false},{"pmid":"36687441","id":"PMC_36687441","title":"Immunoregulatory functions of mature CD10+ and immature CD10- neutrophils in sepsis patients.","date":"2023","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36687441","citation_count":14,"is_preprint":false},{"pmid":"23339695","id":"PMC_23339695","title":"CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.","date":"2012","source":"Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23339695","citation_count":14,"is_preprint":false},{"pmid":"1833412","id":"PMC_1833412","title":"CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.","date":"1991","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/1833412","citation_count":14,"is_preprint":false},{"pmid":"15968199","id":"PMC_15968199","title":"Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma.","date":"2005","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/15968199","citation_count":13,"is_preprint":false},{"pmid":"31929699","id":"PMC_31929699","title":"Immunohistochemical expression of Ki-67, p53, and CD10 in phyllodes tumor and their correlation with its histological grade.","date":"2019","source":"Journal of laboratory physicians","url":"https://pubmed.ncbi.nlm.nih.gov/31929699","citation_count":13,"is_preprint":false},{"pmid":"9337153","id":"PMC_9337153","title":"CD10 is expressed on human thymic epithelial cell lines and modulates thymopentin-induced cell proliferation.","date":"1997","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9337153","citation_count":13,"is_preprint":false},{"pmid":"26788151","id":"PMC_26788151","title":"Significance of androgen receptor and CD10 expression in cutaneous basal cell carcinoma and trichoepithelioma.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26788151","citation_count":13,"is_preprint":false},{"pmid":"37689767","id":"PMC_37689767","title":"Chromosome level genome assembly of colored calla lily (Zantedeschia elliottiana).","date":"2023","source":"Scientific data","url":"https://pubmed.ncbi.nlm.nih.gov/37689767","citation_count":12,"is_preprint":false},{"pmid":"28346124","id":"PMC_28346124","title":"Pax8, Napsin A, and CD10 as Immunohistochemical Markers of Canine Renal Cell Carcinoma.","date":"2017","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28346124","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53209,"output_tokens":5366,"usd":0.120058,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14089,"output_tokens":3949,"usd":0.084585,"stage2_stop_reason":"end_turn"},"total_usd":0.204643,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"CD10/NEP (neutral endopeptidase 24.11) enzymatic activity on neutrophil cell surfaces hydrolyzes inflammatory peptides including f-MLP and substance P, thereby controlling neutrophil responsiveness; inhibition of CD10/NEP enzymatic activity potentiates f-MLP- and substance P-induced changes in neutrophil morphology, migration, and adhesion molecule expression (upregulation of Mo1/CD11b/CD18 and shedding of LAM-1). CD10/NEP enzymatic activity is itself regulated by the activation state of the neutrophil.\",\n      \"method\": \"Cell-based enzyme inhibition assays, flow cytometry for adhesion molecules, neutrophil migration assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays (inhibitor studies, migration, adhesion marker upregulation) in a focused mechanistic study; replicated conceptually across multiple inflammatory peptide substrates\",\n      \"pmids\": [\"1717072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"cALLA (CD10) expressed on glioma cell lines is enzymatically active neutral endopeptidase (NEP), as demonstrated by phosphoramidon-inhibitable endopeptidase activity and the presence of NEP-specific mRNA; surface expression of cALLA directly correlates with functional NEP enzymatic activity.\",\n      \"method\": \"Enzyme activity assay with phosphoramidon inhibition, immunostaining with anti-NEP and anti-cALLA antibodies, Northern blot for NEP mRNA\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic activity assay with specific inhibitor plus orthogonal molecular confirmation (mRNA, two antibody sets); replicated across 10 glioma cell lines\",\n      \"pmids\": [\"2531122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"CALLA (CD10) is structurally identical to neutral endopeptidase 3.4.24.11 (NEP); malignant leukemic cells express a functionally active NEP enzyme, and surface CD10 expression correlates with NEP enzymatic activity. No gross alteration in the CD10/CALLA gene was found in leukemic or malignant cell lines.\",\n      \"method\": \"Restriction enzyme hybridization (Southern blot), enzyme activity assays for NEP on leukemia samples and cell lines\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity correlated with surface expression across leukemia and multiple cell lines; single lab but orthogonal methods (molecular and biochemical)\",\n      \"pmids\": [\"1833412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CD10/NEP modulates peptide-mediated proliferation of non-small cell lung carcinoma (NSCLC) cells; cells with lower CD10/NEP expression proliferate more rapidly, and inhibition of cell-surface CD10/NEP enzymatic activity increases cellular growth rate. CD10/NEP expression is inversely correlated with proliferating cell nuclear antigen (PCNA) expression, and NSCLC cells express receptors for mitogenic peptide substrates of CD10/NEP.\",\n      \"method\": \"Immunostaining for CD10/NEP and PCNA, cell proliferation assays with CD10/NEP inhibition, receptor characterization\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional proliferation assay with enzyme inhibition, correlated with PCNA marker; single lab with two orthogonal approaches\",\n      \"pmids\": [\"7962523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CD10 (endopeptidase 24.11) expressed on thymic epithelial cell (TEC) lines cleaves the thymic peptide thymopentin-5 (TP5) at the cell surface, thereby modulating TP5-induced TEC proliferation. Phosphoramidon, a specific endopeptidase 24.11 inhibitor, acts in synergy with TP5 to enhance TEC growth, confirming that CD10-mediated TP5 cleavage limits TP5 mitogenic signaling.\",\n      \"method\": \"Enzyme inhibition with phosphoramidon, cell proliferation assays, peptide cleavage assays at TEC surface\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional enzyme activity and proliferation assays with specific inhibitor; single lab, two orthogonal methods\",\n      \"pmids\": [\"9337153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human cytomegalovirus (HCMV) infection downregulates CD10 (neutral endopeptidase) surface expression and enzyme activity; HCMV reduces CD10 mRNA levels, inhibits glycosylation of newly synthesized CD10 polypeptide chains, and decreases the rate of CD10 synthesis. Downregulation of CD10 by HCMV is independent of viral DNA synthesis (treatment with viral DNA synthesis inhibitor does not block CD10 downregulation), suggesting a mechanism distinct from that used for CD13 downregulation.\",\n      \"method\": \"Flow cytometry for surface expression, enzyme activity assays, metabolic labeling, RT-PCR/Northern blot for mRNA, inhibitor studies\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (surface expression, enzyme activity, mRNA, glycosylation, inhibitor dissection); single lab\",\n      \"pmids\": [\"9792845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"NEP/CD10 is expressed on syncytiotrophoblasts of normal placenta and in gestational trophoblastic diseases (GTDs). NEP enzyme activity in choriocarcinoma cell lines correlates with cell-surface NEP protein levels and is abolished by the NEP inhibitor phosphoramidon. NEP appears as a double band of 95 and 100 kDa in placental and GTD tissues. Differential localization of NEP among trophoblastic tumors (restricted to syncytiotrophoblasts in normal placenta and hydatidiform mole; extended to anaplastic cytotrophoblasts in choriocarcinoma) suggests a role in trophoblast transformation and hCG secretion.\",\n      \"method\": \"Flow cytometry, phosphoramidon enzyme inhibition assay, immunoblot (Western blot), immunohistochemistry\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity correlated with protein expression, inhibitor confirmation, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"11092533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NEP/CD10 expression is induced de novo on HL-60 cells upon jaspamide (jasplakinolide)-induced apoptosis. Once expressed, CD10 enzyme activity interferes with apoptotic signaling: inhibition of CD10 enzymatic activity (by phosphoramidon or anti-CD10 antibody) significantly increases apoptosis. CD10 expression is blocked by monocytic differentiating agents (vitamin D3, PMA) but not granulocytic agents, linking CD10 expression to granulocytic differentiation. A broad-spectrum caspase inhibitor partially blocks CD10 induction, suggesting a connection between apoptosis and CD10 synthesis.\",\n      \"method\": \"Flow cytometry, cycloheximide protein synthesis inhibition, enzyme inhibition (phosphoramidon, anti-CD10 antibody), caspase inhibitor studies, differentiation agent treatments\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological interventions with functional readouts; single lab\",\n      \"pmids\": [\"12363040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Truncating mutations in the MME gene (encoding NEP/CD10) cause absence of NEP protein expression in affected mothers, leading to fetomaternal alloimmunization against fetal NEP antigens on glomerular podocytes during pregnancy. Two compound heterozygous or homozygous mutations were identified (1342C→T nonsense and 446delC frameshift). The severity of neonatal membranous glomerulopathy was determined by the maternal IgG response to fetal NEP, establishing NEP as the podocyte target antigen in antenatal membranous glomerulonephritis.\",\n      \"method\": \"Direct sequencing of genomic PCR products, SNP haplotype analysis, Western blotting for IgG subclasses with anti-NEP activity\",\n      \"journal\": \"Lancet\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct sequencing identified causative loss-of-function mutations, corroborated by protein absence and functional antibody data across multiple families; replicated in three independent families\",\n      \"pmids\": [\"15464186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD10 protease activity is required to prevent differentiation of human mammary progenitors: inhibition of CD10 enzymatic activity promotes differentiation. The CD10-high/EpCAM-low population is enriched for early common progenitors and mammosphere-forming cells. CD10 acts in concert with beta1-integrin adhesion to the basement membrane to maintain the mammary progenitor/stem cell pool.\",\n      \"method\": \"Cell sorting (FACS for CD10 and EpCAM), mammosphere formation assays, enzyme inhibition functional assays, in vitro lineage progression assay\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional enzyme inhibition assay with differentiation readout, combined with prospective cell sorting; single lab, two orthogonal approaches\",\n      \"pmids\": [\"20506111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A common MME nonsynonymous variant (Val73) causes a significant reduction in MME enzyme activity (21% of wild-type) and immunoreactive NEP protein (29% of wild-type). Proteasome-mediated degradation and autophagy both participate in the degradation of this variant allozyme, and upregulation of chaperone proteins BiP and GRP94 after Val73 MME transfection indicates protein misfolding, consistent with MME X-ray crystal structural predictions.\",\n      \"method\": \"COS-1 cell transfection, quantitative Western blot, fluorometric enzyme activity assay, proteasome/autophagy inhibitor studies, chaperone protein analysis\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis (variant allozyme expression), enzymatic activity assay, protein degradation pathway dissection with inhibitors, and chaperone upregulation; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"20692264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD10 is selectively associated with tetraspanin CD9 (but not CD82) on the cell surface. Stable expression of wild-type CD9 in CD10-positive K562 cells enhances CD10 release with exosomes five-fold, whereas CD9 chimera containing the CD82 C-terminal tail has little effect. ShRNA knockdown of CD9 in Nalm-6 pre-B cells reduces endogenous CD10 release in microvesicles two-fold. CD10 peptidase activity correlates with CD10 expression level and is not significantly modulated by CD9 expression per se.\",\n      \"method\": \"Co-immunoprecipitation, chimeric tetraspanin mutagenesis, shRNA knockdown, exosome isolation and quantification, peptidase activity assay\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — binding partner identified by Co-IP and mapped by mutagenesis/chimera studies; functional consequence (exosome release) validated by both overexpression and knockdown; enzymatic activity measured independently\",\n      \"pmids\": [\"23289620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Recessive loss-of-function mutations in MME (encoding neprilysin/NEP) cause autosomal-recessive Charcot-Marie-Tooth type 2 (AR-CMT2T) with late-onset axonal neuropathy; lack/decrease of NEP protein expression was confirmed in peripheral nerve tissue of affected patients. All MME mutations identified were consistent with loss-of-function. The loss-of-function MME mutation did not cause early-onset Alzheimer's disease in affected individuals.\",\n      \"method\": \"Whole-exome sequencing, Sanger sequencing mutation confirmation, immunohistochemical protein expression in peripheral nerve, clinico-pathological characterization\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function variants identified in 10 unrelated patients, protein absence confirmed in nerve tissue; replicated across multiple independent families\",\n      \"pmids\": [\"26991897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Rare heterozygous loss-of-function and missense mutations in MME (neprilysin) cause late-onset autosomal-dominant axonal polyneuropathies with age-related incomplete penetrance. MME mutations result in strongly decreased tissue availability of neprilysin and impaired enzymatic activity in affected individuals.\",\n      \"method\": \"Whole-exome sequencing, Sanger sequencing, nerve tissue neprilysin level measurement, enzymatic activity assay in patient tissue\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutations identified in 19 independent index cases, protein level and enzymatic activity directly measured in patient tissues; replicated across multiple labs/cohorts\",\n      \"pmids\": [\"27588448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A heterozygous MME missense mutation (p.C143Y), affecting a conserved cysteine involved in a disulfide bridge of neprilysin, segregates with dominant spinocerebellar ataxia and polyneuropathy (SCA43) in a five-generation Belgian family, indicating that disruption of this structural disulfide bridge causes dominant disease.\",\n      \"method\": \"Linkage analysis, whole-exome sequencing, Sanger sequencing cosegregation analysis, bioinformatic conservation analysis\",\n      \"journal\": \"Neurology Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic cosegregation in single family with structural prediction; no direct functional protein characterization performed in this paper\",\n      \"pmids\": [\"27583304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MME (neprilysin/CD10) inhibits esophageal squamous cell carcinoma (ESCC) metastasis by inhibiting FAK phosphorylation and thereby disrupting the FAK-RhoA signaling axis, which is important for cell movement. MME overexpression also interrupts ESCC tumor cell adhesion.\",\n      \"method\": \"In vitro and in vivo metastasis assays, Western blot for FAK phosphorylation, RhoA pathway analysis, MME overexpression functional studies\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional overexpression studies with defined molecular readout (FAK phosphorylation, RhoA axis) confirmed in vitro and in vivo; single lab\",\n      \"pmids\": [\"31054987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD10 expression identifies a subset of human adventitial perivascular progenitor cells (CD10+ adventitial cells) with higher proliferation, clonogenic, and osteogenic potentials compared to CD10- counterparts. CD10+ adventitial cells increase expression of cell cycle protein CCND2 via ERK1/2 signaling and osteoblastogenic gene expression via NF-κB signaling. CD10 expression in adventitial cells is upregulated through sonic hedgehog-mediated GLI1 signaling.\",\n      \"method\": \"Cell sorting, clonogenic assays, osteogenic differentiation assays, Western blotting for ERK1/2 and NF-κB pathway components, hedgehog pathway inhibition\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell sorting with functional comparison, pathway inhibition studies; single lab with multiple orthogonal assays\",\n      \"pmids\": [\"31721342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MME variants are the most frequently identified genetic cause of late-onset unexplained axonal neuropathies, accounting for 34.8% of genetically solved cases; transmission is consistent with incompletely penetrant autosomal-dominant inheritance. Low neprilysin blood levels were confirmed in patients with MME variants, supporting a loss-of-function mechanism.\",\n      \"method\": \"Whole-exome sequencing, MME single-gene sequencing, blood neprilysin protein level measurement\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-center study with independent replication cohort; direct protein level measurement in patients; consistent with prior studies\",\n      \"pmids\": [\"33144514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"An MME+ fibro-adipogenic progenitor (FAP) subpopulation has high adipogenic potential and low WNT pathway activity, making it refractory to WNT activator-mediated inhibition of adipogenic commitment. Transplantation experiments confirmed that MME+ FAPs preferentially differentiate into adipocytes under pathological conditions, and MME+ FAPs undergo apoptosis during muscle regeneration, reducing their abundance.\",\n      \"method\": \"Single-nuclei and single-cell RNA sequencing, ex vivo cell characterization, transplantation experiments, WNT pathway inhibitor/activator studies\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transplantation experiments confirm adipogenic fate, WNT pathway mechanistic link shown; single lab with scRNA-seq and functional validation\",\n      \"pmids\": [\"36707617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Inhibition of CD10 enzymatic activity significantly reduced the growth of gastric cancer cell lines MKN28 and AGS, demonstrating that CD10's ability to degrade gastrointestinal peptides plays a role in gastric cancer cell proliferation.\",\n      \"method\": \"Cell proliferation assays with enzyme inhibition\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single pharmacological inhibition assay in cell lines; no mechanistic follow-up on substrate identity\",\n      \"pmids\": [\"15492809\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MME encodes neprilysin (NEP/CD10), a zinc-dependent cell-surface metalloprotease that cleaves a broad range of bioactive peptides (enkephalins, substance P, f-MLP, natriuretic peptides, thymopentin, amyloid-β) at the cell surface to attenuate peptide-mediated signaling; its enzymatic activity controls neutrophil inflammatory responsiveness, mammary progenitor differentiation, lung and gastric carcinoma cell proliferation, and trophoblast biology; interaction with tetraspanin CD9 regulates CD10 exosomal release; loss-of-function MME mutations cause peripheral neuropathy (AR-CMT2T and dominant late-onset polyneuropathy) by reducing neprilysin protein levels and enzymatic activity; and MME suppresses cancer cell metastasis via inhibition of FAK-RhoA signaling, while variant allozymes are degraded by proteasomal and autophagic pathways.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MME encodes neprilysin (NEP/CD10/CALLA), a zinc-dependent cell-surface neutral endopeptidase (EC 3.4.24.11) whose phosphoramidon-inhibitable enzymatic activity cleaves bioactive peptides at the plasma membrane to attenuate peptide-mediated signaling across diverse cell types [#1, #2]. On neutrophils, surface NEP hydrolyzes inflammatory peptides such as f-MLP and substance P, and inhibiting its activity potentiates peptide-driven migration and adhesion-molecule changes (CD11b/CD18 upregulation, LAM-1 shedding), establishing NEP as a brake on inflammatory responsiveness [#0]. The same catalytic mechanism limits peptide-mitogen signaling to constrain proliferation: NEP cleaves thymopentin to restrain thymic epithelial cell growth [#4], and its inhibition or loss accelerates non-small-cell lung carcinoma and gastric carcinoma proliferation [#3]. NEP also regulates cell-fate decisions, maintaining mammary progenitors in an undifferentiated state through its protease activity acting together with beta1-integrin adhesion [#10], and it suppresses esophageal squamous carcinoma metastasis by inhibiting FAK phosphorylation and the downstream FAK-RhoA motility axis [#15]. NEP associates selectively with the tetraspanin CD9, which promotes its release in exosomes/microvesicles without altering its intrinsic peptidase activity [#11]. Loss-of-function MME mutations cause late-onset axonal peripheral neuropathy through both autosomal-recessive (AR-CMT2T) and incompletely penetrant autosomal-dominant inheritance, with reduced neprilysin protein and enzymatic activity confirmed in patient nerve and blood [#12, #13, #17]; truncating maternal mutations also underlie antenatal membranous glomerulonephritis via fetomaternal alloimmunization against podocyte NEP [#8]. A common Val73 variant allozyme misfolds and is degraded by proteasomal and autophagic pathways with chaperone (BiP/GRP94) induction, providing a molecular basis for reduced enzyme availability [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established that the leukemia/glioma surface antigen CD10/cALLA is itself an enzymatically active neutral endopeptidase, unifying an immunophenotypic marker with a defined catalytic activity.\",\n      \"evidence\": \"Phosphoramidon-inhibitable endopeptidase assay, anti-NEP/anti-cALLA immunostaining, and NEP mRNA Northern blot across glioma cell lines\",\n      \"pmids\": [\"2531122\", \"1833412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not enumerate the physiological peptide substrates in these cells\", \"Structural basis of catalysis not addressed\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Defined NEP/CD10 as a regulator of neutrophil inflammatory responsiveness by degrading chemotactic and inflammatory peptides at the cell surface.\",\n      \"evidence\": \"Cell-based enzyme inhibition with migration and adhesion-molecule (CD11b/CD18, LAM-1) flow cytometry readouts in neutrophils\",\n      \"pmids\": [\"1717072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify which substrate dominates in vivo\", \"Mechanism coupling neutrophil activation state to NEP activity unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Extended the peptide-degradation logic to a growth-control role, showing NEP limits peptide-mitogen-driven proliferation of carcinoma cells.\",\n      \"evidence\": \"CD10/NEP inhibition proliferation assays inversely correlated with PCNA in NSCLC; gastric cancer lines confirmed pharmacologically\",\n      \"pmids\": [\"7962523\", \"15492809\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific mitogenic substrate not definitively identified\", \"Gastric finding rests on a single inhibition assay\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Provided substrate-resolved evidence that NEP cleavage of a defined peptide (thymopentin) tunes cell proliferation.\",\n      \"evidence\": \"Phosphoramidon synergy with TP5 and surface peptide-cleavage assays in thymic epithelial cell lines\",\n      \"pmids\": [\"9337153\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream TP5 receptor signaling not mapped\", \"Single cell-line system\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated in humans that complete loss of NEP protein has pathological consequences, identifying NEP as the podocyte antigen in antenatal membranous glomerulonephritis.\",\n      \"evidence\": \"Genomic sequencing of truncating MME mutations in mothers plus anti-NEP IgG subclass analysis across families\",\n      \"pmids\": [\"15464186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address NEP catalytic role in the kidney\", \"Penetrance of alloimmunization not quantified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked a common MME coding variant to reduced enzyme availability via protein misfolding and degradation, giving a mechanistic basis for functional NEP deficiency.\",\n      \"evidence\": \"COS-1 expression of Val73 allozyme with quantitative Western blot, fluorometric activity assay, proteasome/autophagy inhibitors, and BiP/GRP94 analysis\",\n      \"pmids\": [\"20692264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological/clinical penetrance of the variant not established here\", \"Folding defect inferred from crystal-structure prediction, not directly imaged\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed NEP protease activity actively maintains the mammary progenitor pool, expanding its role from signal attenuation to stem-cell fate control.\",\n      \"evidence\": \"FACS isolation of CD10-high/EpCAM-low cells, mammosphere assays, and enzyme inhibition driving differentiation\",\n      \"pmids\": [\"20506111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relevant cleaved substrate maintaining progenitors unknown\", \"Mechanistic interplay with beta1-integrin not molecularly resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified the tetraspanin CD9 as a direct surface partner controlling NEP packaging into exosomes/microvesicles, separating trafficking from intrinsic catalysis.\",\n      \"evidence\": \"Co-IP, CD9/CD82 chimera mutagenesis, shRNA knockdown, and exosome quantification with independent peptidase assays\",\n      \"pmids\": [\"23289620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of NEP exosomal release on recipient cells not tested\", \"CD9-binding interface on NEP not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established MME loss-of-function as a genetic cause of late-onset axonal neuropathy through both recessive and dominant, incompletely penetrant inheritance, with NEP reduction confirmed in patient nerve.\",\n      \"evidence\": \"Whole-exome/Sanger sequencing across multiple cohorts plus immunohistochemical and enzymatic confirmation in peripheral nerve; one family showed a disulfide-disrupting p.C143Y in SCA43\",\n      \"pmids\": [\"26991897\", \"27588448\", \"27583304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NEP substrate(s) relevant to axonal maintenance not identified\", \"Basis of incomplete penetrance unresolved\", \"C143Y functional consequence inferred from structure, not assayed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a non-proteolytic-context tumor-suppressor mechanism in which MME restrains metastasis by inhibiting FAK-RhoA signaling and cell adhesion.\",\n      \"evidence\": \"MME overexpression in vitro/in vivo metastasis assays with Western blot for FAK phosphorylation and RhoA pathway analysis in ESCC\",\n      \"pmids\": [\"31054987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether enzymatic activity is required for FAK inhibition not dissected\", \"Single cancer-type, single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Positioned MME as a marker of progenitor subpopulations with distinct fate biases, including adipogenic FAPs refractory to WNT-mediated suppression and CD10+ adventitial osteogenic progenitors.\",\n      \"evidence\": \"scRNA/snRNA-seq, transplantation, and WNT/hedgehog pathway perturbation in FAP and adventitial progenitor systems\",\n      \"pmids\": [\"36707617\", \"31721342\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NEP enzymatic activity drives these fate outcomes or is merely a marker is unclear\", \"Substrates relevant to FAP/adventitial biology not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The physiological substrate(s) of neprilysin whose accumulation drives axonal neuropathy, and whether catalytic versus scaffolding functions account for its progenitor and tumor-suppressor roles, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined substrate links NEP loss to axon degeneration\", \"Catalytic vs non-catalytic contribution to FAK-RhoA inhibition and progenitor maintenance not separated\", \"No structural model of NEP-CD9 or variant misfolding directly validated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 2, 4, 6]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 6, 11]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 16, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 12, 13, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CD9\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}